Nanomath LLC

Executive Summary

Nanomath LLC is a specialized modeling and simulation company based in Cambridge, MA, focused on pharmacokinetics (PK), pharmacodynamics (PD), and systems biology. Founded in 2018, the company develops and distributes SAAM II, a leading software platform for analyzing complex biological systems and optimizing drug dosing. Operating as a service and software provider, Nanomath serves the pharmaceutical and medical device industries, offering expertise that accelerates drug development and regulatory submissions. As a private, early-stage firm with no disclosed funding, Nanomath occupies a niche but critical role in the increasingly quantitative drug development landscape. The adoption of model-informed drug development (MIDD) by regulators like the FDA positions Nanomath for growth, though its small scale and reliance on a single flagship product present risks.

Upcoming Catalysts (preview)

• Q4 2026Release of SAAM II Version 5.0 with enhanced machine learning integration60% success
• Q2 2027Strategic partnership with a top-20 pharmaceutical company for model-based clinical trial optimization45% success
• Q3 2026Expansion into oncology therapeutic modeling services50% success